Ads
related to: drug relapse
Search results
Q1 2024 Bio Path Holdings Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoA third cohort includes treating refractory relapsed AML patients who are venetoclax resistant or intolerant with the two-drug combination of prexigebersen ...
Slovakian PM's Prognosis; Kate Middleton's Treatment; Drug Test Cheating
MedPage Today· 5 days agoThe FDA gave accelerated approval to lisocabtagene maraleucel (Breyanzi) for adults with relapsed or...
AP Investigation: In hundreds of deadly police encounters, officers broke multiple safety guidelines
WOOD via Yahoo News· 6 days agoIn hundreds of deaths where police used force meant to stop someone without killing them, officers...
Jamie-Lynn Sigler Calls Ozempic Triggering: ‘It’s Upsetting Me’
US Weekly· 7 days agoJamie-Lynn Sigler says she feels ‘triggered’ by the ongoing wave of Ozempic and Mounjaro weight loss...
Jamie-Lynn Sigler Says She’s ‘Triggered’ By Ozempic, Recalls Eating Disorder
Us Weekly via Yahoo News· 7 days agoJamie-Lynn Sigler says she feels ‘triggered’ by the ongoing wave of Ozempic and Mounjaro weight loss...
Help awaits for those struggling with their mental health, alliance wants them to know
Park Record· 4 days agoAfter hitting bottom in her mid-30s, Wheelock went into treatment for intravenous drug abuse and...
Erasca restructures; Novartis moves to complete MorphoSys deal
BioPharma Dive via Yahoo Finance· 4 days agoThe cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere,...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 7 days agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid...
No Improvement in OS With Atezolizumab in Relapsing TNBC
Medscape· 5 days agoEarly relapsing disease has again shown the limitations of immunotherapy in triple-negative breast...
FDA Broadens Breyanzi's Follicular Lymphoma Indication
Medscape· 5 days agoThe overall response rate to the CAR T therapy was 95.7% in phase 2 testing.
